Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) had its price target increased by Piper Sandler from $9.00 to $11.00 in a ...

Sandoz Inc., Pfizer Inc., and Amneal Pharmaceuticals Inc. are among a group of generic-drug manufacturers that will face some ...

On Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported third-quarter adjusted EPS of $0.16, down from $0.19 a year ago, ...

Q3 2024 Earnings Call Transcript November 8, 2024 Amneal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Aigen Investment Management LP purchased a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional ...

Amneal Pharmaceuticals (NASDAQ:AMRX) is scheduled to announce Q3 earnings results on Friday, November 8th, before market open ...

Analysts are estimating that Amneal Pharmaceuticals will report an earnings per share (EPS) of $0.13. The announcement from ...

As the FTC continues to crack down on pharmaceutical manufacturers’ allegedly improper listing of patents in the FDA Orange ...

Amneal Pharmaceuticals, Inc. (AMRX), a generics and specialty pharmaceutical company, on Friday reported net loss for the third ...

Piper Sandler raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $11 from $9 and keeps an Overweight rating on the ...

While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics ...